World Medical Association. Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. JAMA.
Latimer, NR, Abrams, KR, Lambert, PC, et al. Adjusting survival time estimates to account for treatment switching in randomised controlled trials – An economic evaluation context: Methods, limitations and recommendations. Med Decis Making.
Jonsson, L, Sandin, R, Ekman, M, et al.
Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. Value Health.
Ishak, KJ, Proskorovsky, I, Korytowsky, B, et al.
Methods for adjusting for bias due to crossover in oncology trials. Pharmacoeconomics.
Henshall, C, Latimer, NR, Sansom, L, Ward, R. Treatment switching in clinical trials: Issues and proposals following the 2014 Adelaide International Workshop, IJTAHC
Moher, D, Schulz, KF, Altman, DG.
CONSORT GROUP (Consolidated Standards of Reporting Trials). The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med.
Intention to treat: Once randomized, always analyzed. Clin Aphasiol.
Intention-to-treat concept: A review. Perspect Clin Res.
Lee, Y, Ellenberg, J, Hirtz, D, Nelson, K.
Analysis of clinical trials by treatment actually received: is it really an option?
Horwitz, R, Horwitz, S.
Adherence to treatment and health outcomes. Arch Intern Med.
Morden, JP, Lambert, PC, Latimer, NR, Abrams, KR, Wailoo, AJ.
Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study. BMC Med Res Methodol.
Latimer, N, Abrams, K, Lambert, P, et al. Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method. Stat Methods Med Res.
Latimer, NR, Abrams, KR, Lambert, PC, Morden, JP, Crowther, MJ.
Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study. Stat Methods Med Res.
Hernan, MA, Brumback, B, Robins, JM.
Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Statist Assoc.
Regression models and life tables (with Discussion). J R Stat Soc Series B Stat Methodol.
Robins, JM, Finkelstein, DM.
Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics.
White, IR, Babiker, AG, Walker, S, Darbyshire, JH.
Randomization-based methods for correcting for treatment changes: Examples from the Concorde trial. Stat Med.
Robins, JM, Tsiatis, AA.
Correcting for noncompliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods.
Robins, JM, Greenland, S.
Adjusting for differential rates of prophylaxis therapy for Pcp in high-dose versus low-dose Azt treatment arms in an aids randomized trial. J Am Stat Assoc.
Yamaguchi, T, Ohashi, Y.
Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: An application in a clinical trial of unresectable non-small-cell lung cancer. Stat Med.
Howe, CJ, Cole, SR, Chmiel, JS, Munoz, A. Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias. Am J Epidemiol.
Drummond, M, Evans, B, LeLorier, J, et al.
Evidence and values: Requirements for public reimbursement of drugs for rare diseases – A case study in oncology. Can J Clin Pharmacol.